Streetbeat News

Regulatory

AMGN

AZN

Amgen and AstraZeneca announced results from the Phase 2a COURSE trial of Tezspire for severe COPD, showing mixed efficacy results. The drug showed a 17% reduction in COPD exacerbations overall, but more significant reductions in specific patient subgroups. The safety profile was consistent with its approved severe asthma indication.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 6:38 pm

ESPR

Esperion Therapeutics and Otsuka Pharmaceutical announced that their partnered cholesterol drug, bempedoic acid, achieved the primary endpoint in a Phase 3 trial in Japan. The trial showed statistically significant positive outcomes for patients with high LDL cholesterol. Otsuka plans to submit a New Drug Application in Japan in late 2024. Additionally, Esperion received a U.S. Patent Term Extension for bempedoic acid, extending its patent through December 2030. Following the news, Esperion's stock rose by 5.51%.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 6:22 pm

MDT

Medtronic's Sphere-9 catheter has demonstrated safety and efficacy in treating atrial fibrillation, outperforming the conventional Thermocool SmartTouch SF catheter in a clinical study. The results were presented at the Heart Rhythm Society 2024 Annual Meeting and published in Nature Medicine. The Sphere-9 catheter showed a favorable safety profile and superior procedural efficiency, leading to improved patient outcomes.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 6:22 pm

SPY

Federal Reserve's Mester has revised her expectations, stating that she no longer anticipates three rate cuts this year, which could impact market sentiment.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:13 pm

SPY

Federal Reserve's Mester suggests that the neutral interest rate may be higher than previously estimated, and she raised her estimate in March.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:12 pm

SPY

Federal Reserve's Mester stated that the Fed could cut rates if there is an unforeseen deterioration in the real economy. Conversely, if inflation stalls or reverses, the Fed may hold or even raise rates. Mester emphasized the need for careful monitoring of the economy.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:11 pm

SPY

Federal Reserve's Mester believes inflation will decrease but not quickly. She states that current policies are well-positioned to handle risks on either side.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:10 pm

SPY

Federal Reserve's Mester states that monetary policy is moderating demand, but the pace is slower than anticipated.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:09 pm

SPY

Federal Reserve's Mester expressed concerns over the lack of progress on inflation but noted that there is no risk in spending more time gathering data due to the strong economy.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:08 pm

SPY

Federal Reserve's Mester stated that she does not consider the timing of potential rate cuts, emphasizing that any decision will depend on progress with inflation.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:07 pm